+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

EU (European Union) Pharmaceutical Regulations & Strategy Training Course (ONLINE EVENT: October 6-7, 2025)

  • Training

  • 2 Days
  • Region: Europe
  • Oct 6th 09:30 - Oct 7th 17:00 GMT+1
  • IPI Academy
  • ID: 6042085
OFF until Sep 01st 2025

In the highly regulated field of pharmaceuticals, staying abreast of regulatory affairs is crucial for ensuring compliance, maintaining market authorisations, and effectively managing drug development and post-approval obligations. Navigating the complexities of regulatory processes, particularly in the context of evolving legislation, can be challenging. This is where a comprehensive understanding of pharmaceutical regulatory affairs becomes indispensable. 

Creating and coordinating an effective regulatory strategy is an essential part of the work of a regulatory affairs department and can save valuable time and money. It is therefore important to be aware of potential changes which may impact on strategy.

This interactive course will provide an overview of the current European pharmaceutical regulatory environment, procedures and obligations and discuss how to interpret and apply the legislation. The proposed EU pharmaceuticals legislation changes will be discussed in the relevant sections.

The programme will cover the legal basis of regulation, development strategies and the importance of pre-submission activities as well a brief overview of the format for presentation of data, the registration procedures for obtaining marketing authorisations and post-authorisation obligations and strategic considerations.

The  UK is no longer part of the EU but knowledge of interactions and collaboration with the EU and other regulatory agencies are important for obtaining and maintaining marketing authorisations in the UK. Case study sessions will explore options and strategies for key regulatory activities and  provide an opportunity for discussion and the sharing of experiences with our expert trainer and other delegates.

Benefits of attending

  • Understand the legal basis of the current EU regulatory environment
  • Outline the background to and the proposed EU pharmaceutical legislation changes
  • Discuss development strategy and pre-submission activities
  • Review procedures for applying for a marketing authorisation in the EU/EEA and in the UK
  • Discuss post-authorisation strategic considerations and obligations

Certifications:

  • CPD: 12 hours for your records
  • Certificate of completion

Course Content


Day 1
EU regulatory environment: legal basis
  • Key regulations, directives and guidelines
  • Proposed EU pharmaceuticals legislation changes Information sources
Information sourcesCase Study One
Development and Strategy
  • Drug discovery
  • Scientific advice
Development process
  • Pharmaceutical R&D
  • Non-clinical tests
  • Clinical studies - Phase I to III
EU Clinical Trials RegulationTypes and categories of marketing AuthorisationsAdaptive marketing authorisation procedures
The Common Technical Document (CTD)
  • Overview of Structure and content of a CTD
Procedures for obtaining a marketing authorisation in the EU and EMA
  • The EU centralised procedure
Other EU centralised procedures
  • Referral and arbitration
Day 2
Other procedures for obtaining a marketing authorisation in the EU
  • Coordination group
  • Decentralised procedure (DCP)
  • Mutual recognition procedure (MRP)
  • National procedures
Managing product labellingCase Study Two
Abridged applications and Generics
  • Types and Requirements
Product Life Cycle; Post approvalPatents and SPCsParallel tradePost-authorisation obligations; pharmacovigilance, variations and renewalsPharmacovigilance
Licence variations
  • Type I and Type II variations and timelines
  • Procedures and timelines
ExtensionsCase Study ThreeRenewalsSunset clausePhase IV TrialsClassification changeGeneric developmentStrategic factorsCriteria for successful products